• Price (EUR)15.25
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-16.16%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2022 20:55 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a medical technology company. The Company is engaged in designing and manufacturing technology. It supports healthcare professionals to return their patients to health and mobility by helping them to perform. It serves its customers through global franchises, which includes Orthopaedics, Sports Medicine and Ear, Nose and Throat (ENT) and Advanced Wound Management. The Orthopaedics includes a range of Hip and Knee Implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that allow surgeons, and Trauma products used to stabilize severe fractures and correct bone deformities. Its Sports Medicine and ENT businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a set of products to meet clinical needs, to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)4.17bn
  • Net income in GBP419.63m
  • Incorporated1937
  • Employees18.37k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttp://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SN.:LSE since
Engage SurgicalDeal completed19 Jan 202219 Jan 2022Deal completed3.70%135.00m
Data delayed at least 20 minutes, as of May 23 2022 17:13 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.